Top Markets
Coin of the day
Biocartis Group N.V. Biocartis Group N.V.

Biocartis Group N.V.

BCART
Ранг среди акций #27531
Biocartis Group NV is a molecular diagnostics firm dedicated to improving... Biocartis Group NV is a molecular diagnostics firm dedicated to improving clinical care. Its innovative diagnostic solutions primarily serve the oncology sector, benefiting patients, medical professionals, insurers, and the broader healthcare ecosystem. The company's cornerstone is its exclusive Idylla molecular diagnostics platform, a sophisticated real-time polymerase chain reaction (PCR) system. This technology delivers crucial molecular data, aiding in the selection of appropriate treatments and the continuous monitoring of patient progress. Biocartis offers a range of diagnostic tests via the Idylla system, including mutation analysis for BRAF, KRAS, MSI, EGFR, and NRAS-BRAF. Additionally, it provides Idylla panels for SARS-CoV-2/Flu/RSV, standalone SARS-CoV-2 tests, and the rapid host-response assessment, SeptiCyte RAPID. For research purposes, the company supplies various mutation assays, such as those for MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R. Biocartis has entered into strategic partnerships to broaden its impact. One such collaboration is with Amgen, focusing on evaluating Idylla RAS testing to enable swift, decentralized diagnostics and enhance the accessibility of RAS biomarker data through the Idylla platform and its associated RAS tests. Another key alliance is with Bristol-Myers Squibb Company, centered on the registration and application of the Idylla MSI test within the field of immuno-oncology treatments. Furthermore, a licensing, development, and commercialization agreement with GeneproDx is in place for the creation of the innovative ThyroidPrint genomic test, to be integrated onto the Idylla platform. Established in 2007, Biocartis maintains its corporate headquarters in Mechelen, Belgium.
Цена акции
$0.343985
Последняя синхронизация: 2024-07-23
Рыночная капитализация
$32.31M
Изменение (1 день)
11.88%
Изменение (1 год)
0.00%
Страна
BE
Торговля Biocartis Group N.V. (BCART)

Категория

Коэффициент P/S для Biocartis Group N.V. (BCART)
Коэффициент P/S на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Biocartis Group N.V., текущий коэффициент P/S (TTM) составляет 0. В конце 2026 он составлял 0.
История P/S для Biocartis Group N.V. с 2026 по 2026
Коэффициент P/S в конце каждого года
Год P/S Изменить
Недостаточно данных для указанных дат.
Коэффициент P/S для аналогичных компаний или конкурентов
Компания P/S Разница P/S Страна
4.72 -
US
5.67 -
US
- -
CN
16.40 -
US
9.55 -
US